SG11201607693WA - 6-substituted estradiol derivatives for the treatment of alzheimer's disease - Google Patents
6-substituted estradiol derivatives for the treatment of alzheimer's diseaseInfo
- Publication number
- SG11201607693WA SG11201607693WA SG11201607693WA SG11201607693WA SG11201607693WA SG 11201607693W A SG11201607693W A SG 11201607693WA SG 11201607693W A SG11201607693W A SG 11201607693WA SG 11201607693W A SG11201607693W A SG 11201607693WA SG 11201607693W A SG11201607693W A SG 11201607693WA
- Authority
- SG
- Singapore
- Prior art keywords
- alzheimer
- disease
- treatment
- estradiol derivatives
- substituted estradiol
- Prior art date
Links
- 208000024827 Alzheimer disease Diseases 0.000 title 1
- 150000002159 estradiols Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461955578P | 2014-03-19 | 2014-03-19 | |
| PCT/US2015/021538 WO2015143201A2 (en) | 2014-03-19 | 2015-03-19 | 6-substituted estradiol derivatives for the treatment of alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201607693WA true SG11201607693WA (en) | 2016-10-28 |
Family
ID=54141046
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201607693WA SG11201607693WA (en) | 2014-03-19 | 2015-03-19 | 6-substituted estradiol derivatives for the treatment of alzheimer's disease |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20150265630A1 (https=) |
| EP (1) | EP3119402A4 (https=) |
| JP (1) | JP2017512769A (https=) |
| KR (1) | KR20160136363A (https=) |
| CN (1) | CN106255501A (https=) |
| AU (2) | AU2015231172A1 (https=) |
| BR (1) | BR112016021408A2 (https=) |
| CA (1) | CA2940536A1 (https=) |
| MX (1) | MX2016012045A (https=) |
| SG (1) | SG11201607693WA (https=) |
| WO (1) | WO2015143201A2 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020247407A1 (en) * | 2019-06-03 | 2020-12-10 | Aihol Corporation | Hyaluronan conjugates and uses thereof |
| US20210024568A1 (en) * | 2019-07-23 | 2021-01-28 | Endece Llc | Methods for modulation of lipoprotein lipase and apolipoprotein c2 expression and/or activity in the treatment of peripheral and central nervous system tissue disease states |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10174070B2 (en) * | 2005-09-30 | 2019-01-08 | Endece Llc | 6-substituted estradiol derivatives and methods of use |
| US20080200441A1 (en) * | 2007-02-14 | 2008-08-21 | University Of Southern California | Estrogen receptor modulators associated pharmaceutical compositions and methods of use |
| CN106420767A (zh) * | 2011-03-21 | 2017-02-22 | 安德斯有限责任公司 | 用于神经轴突的髓鞘再生的6‑取代的雌二醇衍生物 |
-
2015
- 2015-03-19 SG SG11201607693WA patent/SG11201607693WA/en unknown
- 2015-03-19 EP EP15765290.0A patent/EP3119402A4/en not_active Withdrawn
- 2015-03-19 MX MX2016012045A patent/MX2016012045A/es unknown
- 2015-03-19 AU AU2015231172A patent/AU2015231172A1/en not_active Abandoned
- 2015-03-19 JP JP2016556841A patent/JP2017512769A/ja active Pending
- 2015-03-19 KR KR1020167028986A patent/KR20160136363A/ko not_active Withdrawn
- 2015-03-19 BR BR112016021408A patent/BR112016021408A2/pt not_active IP Right Cessation
- 2015-03-19 CA CA2940536A patent/CA2940536A1/en not_active Abandoned
- 2015-03-19 CN CN201580014623.7A patent/CN106255501A/zh active Pending
- 2015-03-19 WO PCT/US2015/021538 patent/WO2015143201A2/en not_active Ceased
- 2015-03-19 US US14/663,043 patent/US20150265630A1/en not_active Abandoned
-
2018
- 2018-02-12 AU AU2018201003A patent/AU2018201003A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN106255501A (zh) | 2016-12-21 |
| JP2017512769A (ja) | 2017-05-25 |
| EP3119402A2 (en) | 2017-01-25 |
| BR112016021408A2 (pt) | 2017-12-19 |
| KR20160136363A (ko) | 2016-11-29 |
| EP3119402A4 (en) | 2017-11-01 |
| AU2015231172A1 (en) | 2016-09-08 |
| CA2940536A1 (en) | 2015-09-24 |
| MX2016012045A (es) | 2017-01-19 |
| WO2015143201A2 (en) | 2015-09-24 |
| AU2018201003A1 (en) | 2018-03-01 |
| US20150265630A1 (en) | 2015-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL280530A (en) | Decarboxylase aromatic amino acid-encoding phylonucleotides for the treatment of Parkinson's disease | |
| IL252433B (en) | Methods for treating Alzheimer's disease | |
| ZA201608108B (en) | Huntington's disease therapeutic compounds | |
| EP3268086A4 (en) | Lsd for the treatment of alzheimer's disease | |
| IL247085B (en) | Methods for treating Alzheimer's disease | |
| PL2968218T3 (pl) | Skojarzenie do leczenia choroby parkinsona | |
| ZA201605341B (en) | Methods of treating alzheimer's disease | |
| IL249502B (en) | New therapeutic uses of benzylideneguanidine derivatives for the treatment of diseases caused by structurally abnormal proteins | |
| IL263188B (en) | Treatment for Parkinson's disease | |
| HUE070257T2 (hu) | Vegyületek a lipofuscinhoz kapcsolódó betegségek kezelésére | |
| IL254252A0 (en) | History of Tetrahydrofuran-Oahe Aminohydrothiazine Usefulness in the Treatment of Alzheimer's Disease | |
| SG11201607693WA (en) | 6-substituted estradiol derivatives for the treatment of alzheimer's disease | |
| EP3244897A4 (en) | Methods for treating alzheimer's disease | |
| HUE039425T2 (hu) | 3,4-Diamino-6-klórpirazin-2-karboxamid vegyületek enac által mediált betegségek kezelésére | |
| DK3148588T3 (en) | N,n-bis-2-mercaptoethyl isophthalamide for the treatment of parkinson's disease | |
| ZA201807944B (en) | Treatment for parkinson's disease | |
| GB201511453D0 (en) | Treatment of alzheimer's disease | |
| GB201414038D0 (en) | Alzheimer's disease | |
| EP3122356A4 (en) | Treatment of parkinson's disease through arfgap1 inhibition using substituted piperazine derivatives |